Literature DB >> 32601335

Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis.

Stefano Alivernini1,2,3,4, Lucy MacDonald5,6, Aziza Elmesmari5,6, Samuel Finlay5,6, Barbara Tolusso7, Maria Rita Gigante7, Luca Petricca7, Clara Di Mario8, Laura Bui9, Simone Perniola8, Moustafa Attar10, Marco Gessi9, Anna Laura Fedele7, Sabarinadh Chilaka6, Domenico Somma6, Stephen N Sansom5,10, Andrew Filer5,11,12, Charles McSharry6, Neal L Millar6, Kristina Kirschner13, Alessandra Nerviani14, Myles J Lewis14, Costantino Pitzalis14, Andrew R Clark5,11, Gianfranco Ferraccioli8, Irina Udalova5,10, Christopher D Buckley5,10,11,12, Elisa Gremese5,7,8, Iain B McInnes5,6, Thomas D Otto15,16, Mariola Kurowska-Stolarska17,18.   

Abstract

Immune-regulatory mechanisms of drug-free remission in rheumatoid arthritis (RA) are unknown. We hypothesized that synovial tissue macrophages (STM), which persist in remission, contribute to joint homeostasis. We used single-cell transcriptomics to profile 32,000 STMs and identified phenotypic changes in patients with early/active RA, treatment-refractory/active RA and RA in sustained remission. Each clinical state was characterized by different frequencies of nine discrete phenotypic clusters within four distinct STM subpopulations with diverse homeostatic, regulatory and inflammatory functions. This cellular atlas, combined with deep-phenotypic, spatial and functional analyses of synovial biopsy fluorescent activated cell sorted STMs, revealed two STM subpopulations (MerTKposTREM2high and MerTKposLYVE1pos) with unique remission transcriptomic signatures enriched in negative regulators of inflammation. These STMs were potent producers of inflammation-resolving lipid mediators and induced the repair response of synovial fibroblasts in vitro. A low proportion of MerTKpos STMs in remission was associated with increased risk of disease flare after treatment cessation. Therapeutic modulation of MerTKpos STM subpopulations could therefore be a potential treatment strategy for RA.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32601335     DOI: 10.1038/s41591-020-0939-8

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  86 in total

1.  Synovial macrophage populations linked to RA remission.

Authors:  Jessica McHugh
Journal:  Nat Rev Rheumatol       Date:  2020-09       Impact factor: 20.543

Review 2.  Precision medicine in rheumatoid arthritis.

Authors:  Kartik Bhamidipati; Kevin Wei
Journal:  Best Pract Res Clin Rheumatol       Date:  2022-03-02       Impact factor: 4.098

3.  Can we treat inflammation by managing misbehaving monocytes?

Authors:  Simon Milling
Journal:  Immunology       Date:  2021-05       Impact factor: 7.397

Review 4.  Fibroblasts as immune regulators in infection, inflammation and cancer.

Authors:  Sarah Davidson; Mark Coles; Tom Thomas; George Kollias; Burkhard Ludewig; Shannon Turley; Michael Brenner; Christopher D Buckley
Journal:  Nat Rev Immunol       Date:  2021-04-28       Impact factor: 53.106

Review 5.  Location, location, location: how the tissue microenvironment affects inflammation in RA.

Authors:  Christopher D Buckley; Caroline Ospelt; Steffen Gay; Kim S Midwood
Journal:  Nat Rev Rheumatol       Date:  2021-02-01       Impact factor: 20.543

Review 6.  Why remission is not enough: underlying disease mechanisms in RA that prevent cure.

Authors:  Georg Schett; Yoshiya Tanaka; John D Isaacs
Journal:  Nat Rev Rheumatol       Date:  2020-12-10       Impact factor: 20.543

Review 7.  Synovial biopsies in clinical practice and research: current developments and perspectives.

Authors:  Hanna Johnsson; Aurélie Najm
Journal:  Clin Rheumatol       Date:  2020-12-04       Impact factor: 2.980

8.  Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages.

Authors:  Florian Wanke; Simon Gutbier; Anna Rümmelin; Malte Steinberg; Lindsey D Hughes; Mascha Koenen; Juliana Komuczki; Daniel Regan-Komito; Sagie Wagage; Julia Hesselmann; Ralf Thoma; Doris Brugger; Tony Christopeit; Hayian Wang; Floriane Point; Remy Hallet; Sourav Ghosh; Carla V Rothlin; Christoph Patsch; Barbara Geering
Journal:  Cell Death Dis       Date:  2021-05-25       Impact factor: 8.469

Review 9.  Macrophage reprogramming for therapy.

Authors:  Valentina M T Bart; Robert J Pickering; Philip R Taylor; Natacha Ipseiz
Journal:  Immunology       Date:  2021-01-25       Impact factor: 7.215

Review 10.  A Tale of Two Immune Cells in Rheumatoid Arthritis: The Crosstalk Between Macrophages and T Cells in the Synovium.

Authors:  Jiajie Tu; Wei Huang; Weiwei Zhang; Jiawei Mei; Chen Zhu
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.